Retatrutide 30mg Peptide
Research Use Only
Get Notified When Available
This product is currently out of stock. Enter your email and we'll notify you the moment it's back.
Research Use Only
For in vitro laboratory research by qualified professionals only. Not for human or animal administration. Not intended to treat, prevent, mitigate, or cure any disease. Batch-specific Certificates of Analysis available for all products.
Research Use Only
For in vitro laboratory research by qualified professionals only. Not for human or animal administration. Not intended to treat, prevent, mitigate, or cure any disease. Batch-specific Certificates of Analysis available for all products.
This 30mg vial is the largest retatrutide presentation in the catalogue, supplying enough material for extended in vitro protocols without repeated reconstitution. Retatrutide is among the most actively studied compounds in the anti-obesity peptide field, and comparative work against semaglutide and tirzepatide is the most common use for larger vials, since parallel arms consume material quickly. Each batch is HPLC-verified for purity and identity with a lot-specific certificate of analysis.
Frequently Bought Together
Retatrutide 30mg
30mg
$159 USD
Bundle & Save
$259 USD
Save $14 USD
$324 USD
Save $34 USD
$369 USD
Save $54 USD
$469 USD
Save $94 USD
Click any product above to toggle selection
Related Peptides
Related Research News
Retatrutide in Canada: Evidence, Safety, and Access
This article clarifies retatrutide's tri-agonist mechanism, reviews the clinical evidence and its gaps, and outlines legal and safety considerations for Canadian research purchases.
Retatrutide vs Mounjaro: Evidence, Limits, and Tradeoffs
This reference evaluates how far current evidence supports using retatrutide over tirzepatide, highlighting that no head-to-head trial exists and that comparative outcomes remain unmeasured.
Retatrutide in Canada: Access, Trials, and Approval Timing
Retatrutide is not yet approved in Canada; access is limited to clinical trials. This article outlines the current status, evidence, and realistic timelines for availability.